Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML-Reference-Cited by-同舟云学术

Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML

Published:2024-02-20 Issue:4 Volume:38 Page:762-768
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Shimony Shai^ORCID,Bewersdorf Jan Philipp^ORCID,Shallis Rory M.^ORCID,Liu Yiwen,Schaefer Eva J.,Zeidan Amer M.,Goldberg Aaron D.,Stein Eytan M.,Marcucci Guido^ORCID,Lindsley R. Coleman,Chen Evan C.,Ramos Perez Jorge,Stein Anthony,DeAngelo Daniel J.^ORCID,Neuberg Donna S.^ORCID,Stone Richard M.^ORCID,Ball Brian,Stahl Maximilian

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41375-024-02175-0.pdf

Reference27 articles.

1. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209–21.

2. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136–52.

3. Granfeldt Østgård LS, Medeiros BC, Sengeløv H, Nørgaard M, Andersen MK, Dufva IH, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol. 2015;33:3641–9.

4. Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125:1367–76.

5. Gardin C, Pautas C, Fournier E, Itzykson R, Lemasle E, Bourhis J-H, et al. Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. Blood Adv. 2020;4:1942–9.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations;Expert Review of Hematology;2024-09-13

2. Molecular Features and Treatment Paradigms of Acute Myeloid Leukemia;Biomedicines;2024-08-06

3. Advancements and Challenges in the Treatment of AML;American Society of Clinical Oncology Educational Book;2024-06

4. Venetoclax Resistance in Acute Myeloid Leukemia;Cancers;2024-03-08